Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.

[1]  F. Baldanti,et al.  Human Cytomegalovirus UL131-128 Genes Are Indispensable for Virus Growth in Endothelial Cells and Virus Transfer to Leukocytes , 2009, Journal of Virology.

[2]  A. McGregor,et al.  Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. , 2008, Journal of virological methods.

[3]  F. Baldanti,et al.  Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. , 2008, The Journal of general virology.

[4]  C. Sinzger.  Entry route of HCMV into endothelial cells. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  Qian-chun Yu,et al.  Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells , 2007, Proceedings of the National Academy of Sciences.

[6]  Brent J. Ryckman,et al.  Characterization of the Human Cytomegalovirus gH/gL/UL128-131 Complex That Mediates Entry into Epithelial and Endothelial Cells , 2007, Journal of Virology.

[7]  R. Pass.  Cytomegalovirus (CMV) Envelope Glycoprotein B (gB) Vaccine in Young Women , 2007 .

[8]  G. Milanesi,et al.  Cytomegalovirus UL131-128 Products Promote gB Conformational Transition and gB-gH Interaction during Entry into Endothelial Cells , 2007, Journal of Virology.

[9]  Larry R. Smith,et al.  Novel microneutralization assay for HCMV using automated data collection and analysis , 2007, Journal of Immunological Methods.

[10]  U. Koszinowski,et al.  Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. , 2006, The Journal of general virology.

[11]  W. Britt,et al.  Human Cytomegalovirus Infection Elicits a Glycoprotein M (gM)/gN-Specific Virus-Neutralizing Antibody Response , 2006, Journal of Virology.

[12]  Brent J. Ryckman,et al.  Human Cytomegalovirus Entry into Epithelial and Endothelial Cells Depends on Genes UL128 to UL150 and Occurs by Endocytosis and Low-pH Fusion , 2006, Journal of Virology.

[13]  T. Shenk,et al.  Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Best,et al.  Passive immunization during pregnancy for congenital cytomegalovirus infection. , 2005, The New England journal of medicine.

[15]  T. Shenk,et al.  Human Cytomegalovirus UL131 Open Reading Frame Is Required for Epithelial Cell Tropism , 2005, Journal of Virology.

[16]  G. Milanesi,et al.  Human Cytomegalovirus UL130 Protein Promotes Endothelial Cell Infection through a Producer Cell Modification of the Virion , 2005, Journal of Virology.

[17]  F. Baldanti,et al.  Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. , 2005, The Journal of general virology.

[18]  T. Shenk,et al.  Human cytomegalovirus encodes a highly specific RANTES decoy receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Markus Wagner,et al.  Human Cytomegalovirus UL131-128 Genes Are Indispensable for Virus Growth in Endothelial Cells and Virus Transfer to Leukocytes , 2004, Journal of Virology.

[20]  G. Wilkinson,et al.  Genetic content of wild-type human cytomegalovirus. , 2004, The Journal of general virology.

[21]  G. Hahn,et al.  Tn7-mediated introduction of DNA sequences into bacmid-cloned cytomegalovirus genomes for rapid recombinant virus construction. , 2003, Journal of virological methods.

[22]  W. Britt,et al.  A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. , 1999, The Journal of infectious diseases.

[23]  S. Riddell,et al.  Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. , 1998, The Pediatric infectious disease journal.

[24]  S. Plotkin,et al.  Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. , 1996, The Journal of infectious diseases.

[25]  W. Britt,et al.  Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. , 1996, The Journal of general virology.

[26]  W. Britt,et al.  The outcome of congenital cytomegalovirus infection in relation to maternal antibody status , 1992, The New England journal of medicine.

[27]  G. Rabalais,et al.  Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. , 1992, The Journal of infectious diseases.

[28]  T. Merigan,et al.  Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. , 1991, The Journal of infectious diseases.

[29]  S. Keay,et al.  Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment , 1991, Journal of virology.

[30]  S. Adler,et al.  Detection of cytomegalovirus antibody by enzyme immunoassay and lack of evidence for an effect resulting from strain heterogeneity , 1986, Journal of clinical microbiology.

[31]  H. Friedman,et al.  TOWNE-VACCINE-INDUCED PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER RENAL TRANSPLANTS , 1984, The Lancet.

[32]  S. Adler,et al.  Cytomegalovirus infections in neonates acquired by blood transfusions , 1983, Pediatric infectious disease.

[33]  C. Prober,et al.  Prevention of transfusion-acquired cytomegalovirus infections in newborn infants , 1981 .

[34]  M. Manning,et al.  Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. , 1995, The Journal of infectious diseases.